Proteomics Study by Serum and Platelet With Neurodegeneration Disease Patients

Seoul National University Hospital22 enrolled

Overview

Using to method of Proteomics, for aims to conquer intractable disease, try to access variety experiment. Biomarker is necessary to develop new diagnosis method and target of treatment.

Following Seoul National University Hospital Institutional Review Board approval, obtain serum and platelet with neurodegeneration patients and control group visited the part of neurology, there'll be analysis to differentiate each other diseases use to method Proteomics. Biomarker will be screening via 1D/2D analysis, Mass analysis, database searching- the MASCOT search tool, SWISS-PROT and etc.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Biomarker With Neurodegeneration Patients

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * neurodegeneration patients and control group include dementia patients visited the part of neurology. * over the age of 18 * when participants can understand subject of this study * Total point of Mini Mental state exam(MMSE)should be Under 26 include MCI (mild cognitive impairment) and over GDS score 3points. exclusion criteria: * under eighteen years of age * when participants cannot understand subject of this study * cannot accept this study

Locations (1)

Department of Neurology, Seoul National University Hospital

Seoul, Seoul, South Korea

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.